Analyst: Doug Tsao


Doug Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals.  Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies.

Mr. Tsao is recognized for his expertise in biosimilars and is a frequent speaker on this topic at industry conferences. Prior to Barclays Mr. Tsao  worked at Lehman Brothers and his combined experience spans over ten years at these two firms. Mr. Tsao served as a Special Assistant to U.S. EPA Administrator Carol Browner from 1997-1999, received an MBA/MPH from U.C. Berkeley and graduated cum laude from Middlebury College with High Honors.


H.C. Wainwright & Co